Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Assembly Biosciences (ASMB) over the last 10 years, with Q3 2025 value amounting to $5.7 million.

  • Assembly Biosciences' Other Accumulated Expenses rose 2020.99% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 2020.99%. This contributed to the annual value of $6.9 million for FY2024, which is 1946.38% up from last year.
  • Assembly Biosciences' Other Accumulated Expenses amounted to $5.7 million in Q3 2025, which was up 2020.99% from $3.4 million recorded in Q2 2025.
  • Assembly Biosciences' Other Accumulated Expenses' 5-year high stood at $7.3 million during Q4 2022, with a 5-year trough of $2.1 million in Q1 2024.
  • For the 5-year period, Assembly Biosciences' Other Accumulated Expenses averaged around $4.6 million, with its median value being $4.3 million (2021).
  • As far as peak fluctuations go, Assembly Biosciences' Other Accumulated Expenses crashed by 4274.63% in 2021, and later surged by 2261.97% in 2024.
  • Assembly Biosciences' Other Accumulated Expenses (Quarter) stood at $6.9 million in 2021, then increased by 6.62% to $7.3 million in 2022, then dropped by 21.5% to $5.7 million in 2023, then increased by 19.46% to $6.9 million in 2024, then dropped by 16.53% to $5.7 million in 2025.
  • Its Other Accumulated Expenses stands at $5.7 million for Q3 2025, versus $3.4 million for Q2 2025 and $2.3 million for Q1 2025.